Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney.
Travere Therapeutics (TVTX) Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Results from a confirmatory study evaluating sparsentan in patients with primary IgAN showed that the treatment was associated with kidney function preservation.
Results from a confirmatory study evaluating sparsentan in patients with primary IgAN showed that the treatment was associated with kidney function preservation.